Pheast Therapeutics, a private biotechnology company developing novel therapies to unleash the power of macrophages on aggressive, difficult-to-treat cancers, today announced that the first patient ...

GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson's disease ...

Relay Therapeutics gains capital via licensing, reduces costs, and advances its promising PI3K-alpha inhibitor. See why RLAY ...

FibroBiologics expects its Houston manufacturing lab to increase the company's pace of discovering therapeutics and potential ...

The fund owned 230,724 shares of the company’s stock after purchasing an additional 23,835 shares during the period. American Century Companies Inc.’s holdings in Vir Biotechnology were worth ...

The article continued: The number of annual cancer cases is expected to rise by 20% by 2030 and jump by 75% by 2050, ...

This began a revolution in molecule production that culminated in the founding of Genentech, the first publicly-owned biotech company, in 1976. Like many biotech startups today, Genentech started ...

Explore MicroStrategy's rise as the largest Bitcoin holder. Learn why MSTR stock may outshine 8% STRK dividends for long-term ...

Galderma today announced the launch of Sculptra, the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCAtm) formulation, in China.1-7,11-14 This follows Sculptra's ...

The company has gained international recognition for its biosimilar versions of drugs used in the treatment of autoimmune diseases and cancer. Green Cross Corporation is a leading biotechnology ...